Trial Profile
Novel Therapeutic Approaches for Treatment of CF Patients With W1282X Premature Termination Codon Mutations
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 15 Dec 2023
Price :
$35
*
At a glance
- Drugs Elexacaftor/ivacaftor/tezacaftor (Primary) ; Ivacaftor (Primary) ; Ivacaftor/tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Therapeutic Use
- 06 Dec 2023 Planned End Date changed from 31 Jan 2024 to 31 Jan 2025.
- 06 Dec 2023 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 12 Dec 2022 Planned number of patients changed from 5 to 2.